pharmaphorum September 2, 2024
Screening people in primary care with a wearable heart monitor developed by iRhythm was able to increase diagnoses of atrial fibrillation (AFib) by 52%, although it did not result in a reduction in hospitalisations for stroke.
The GUARD-AF study recruited almost 12,000 patients aged 70 or above across the US who wore the Zio XT single-lead electrocardiogram (ECG) device for two weeks. The aim was to see if it was better at spotting AFib than regular care, which could allow earlier treatment with oral anticoagulants to prevent ischaemic stroke – a common complication associated with the heart rhythm disturbance.
Results presented at the European Society of Cardiology (ESC) congress showed that the higher AFib diagnosis rate over an average 15...
Today's Sponsors
Today's Sponsor